asimov.com

Evaluation du site asimov.com

Asimov — Intelligent Design

 Généré le 30 Mars 2026 15:19

Vieilles statistiques? UPDATE !

Le score est de 56/100

Optimisation du contenu

Titre

Asimov — Intelligent Design

Longueur : 27

Parfait, votre titre contient entre 10 et 70 caractères.

Description

Asimov builds tools to program living cells. We're integrating mammalian synthetic biology with computer-aided design to advance therapeutic applications.

Longueur : 154

Génial, votre balise META description contient entre 70 et 160 caractères.

Mots-clefs

Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.

Propriétés Open Graph

Bien, cette page profite des balises META Open Graph.

Propriété Contenu
type website

Niveaux de titre

H1 H2 H3 H4 H5 H6
1 87 80 0 0 0
  • [H1] Intelligent designof living systems
  • [H2] Enabling the design and manufacture of advanced therapies
  • [H2] Our approach
  • [H2] How to work with us
  • [H2] Two ways to work with us
  • [H2] Built by genetic designers, for biotech builders
  • [H2] Supported by top investors and US research agencies
  • [H2] Partnered with over 25 companies, from small biotechs to big pharma
  • [H2] In the press
  • [H2] Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
  • [H2] Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
  • [H2] Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
  • [H2] Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
  • [H2] Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
  • [H2] Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
  • [H2] Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression
  • [H2] Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression
  • [H2] Optimizing Bispecific Antibody Expression with Amgen
  • [H2] Optimizing Bispecific Antibody Expression with Amgen
  • [H2] Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing
  • [H2] Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing
  • [H2] Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic
  • [H2] Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic
  • [H2] Asimov Enters into Agreement with BARDA's BioMaP Consortium to Advance Production of Medical Countermeasures Against Ebola and Deadly Viruses
  • [H2] Asimov Enters into Agreement with BARDA's BioMaP Consortium to Advance Production of Medical Countermeasures Against Ebola and Deadly Viruses
  • [H2] Asimov Announces IND Approval and Clinical Dosing of Bispecific Antibody Produced Using CHO Edge Expression System
  • [H2] Asimov Announces IND Approval and Clinical Dosing of Bispecific Antibody Produced Using CHO Edge Expression System
  • [H2] Cytiva and Asimov collaborate on next generation cell line design and process development
  • [H2] Cytiva and Asimov collaborate on next generation cell line design and process development
  • [H2] LOTTE BIOLOGICS and Asimov Announce Partnership for Accelerated Cell Line Development And Scaling to GMP Manufacturing
  • [H2] LOTTE BIOLOGICS and Asimov Announce Partnership for Accelerated Cell Line Development And Scaling to GMP Manufacturing
  • [H2] Novo Nordisk license CHO Edge System
  • [H2] Novo Nordisk license CHO Edge System
  • [H2] Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
  • [H2] Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
  • [H2] Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
  • [H2] Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
  • [H2] Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee
  • [H2] Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee
  • [H2] Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
  • [H2] Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
  • [H2] Asimov launches LV Edge Packaging System to optimize lentivirus production
  • [H2] Asimov launches LV Edge Packaging System to optimize lentivirus production
  • [H2] Announcing Asimov Press
  • [H2] Announcing Asimov Press
  • [H2] Asimov Labs
  • [H2] Asimov Labs
  • [H2] Lift Off
  • [H2] Lift Off
  • [H2] Asimov to Present Data on AI-Designed Tissue Specific Promoters at Upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  • [H2] Asimov to Present Data on AI-Designed Tissue Specific Promoters at Upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  • [H2] Asimov Partners With iGEM to Support the Next Generation of Synthetic Biologists
  • [H2] Asimov Partners With iGEM to Support the Next Generation of Synthetic Biologists
  • [H2] Asimov and Center for Breakthrough Medicines Form Strategic Partnership for Viral Vector Production
  • [H2] Asimov and Center for Breakthrough Medicines Form Strategic Partnership for Viral Vector Production
  • [H2] Asimov Raises $200 Million to Advance Therapeutics Design and Manufacturing with Synthetic Biology
  • [H2] Asimov Raises $200 Million to Advance Therapeutics Design and Manufacturing with Synthetic Biology
  • [H2] Drug Manufacture Has One Huge Flaw. This Synthetic Biology Startup Just Raised $200m To Fix It.
  • [H2] Drug Manufacture Has One Huge Flaw. This Synthetic Biology Startup Just Raised $200m To Fix It.
  • [H2] Asimov Selected by DARPA to Develop Artificial Intelligence Design Engine for Synthetic Biology
  • [H2] Asimov Selected by DARPA to Develop Artificial Intelligence Design Engine for Synthetic Biology
  • [H2] MIT Startup Exchange Names Asimov to STEX25
  • [H2] MIT Startup Exchange Names Asimov to STEX25
  • [H2] MIT Spinout Asimov Implements Programming Language for Cells
  • [H2] MIT Spinout Asimov Implements Programming Language for Cells
  • [H2] How Programmable DNA Strands Could Control Healing
  • [H2] How Programmable DNA Strands Could Control Healing
  • [H2] The automatic-design tools that are changing synthetic biology
  • [H2] The automatic-design tools that are changing synthetic biology
  • [H2] Biologists would love to program cells as if they were computer chips
  • [H2] Biologists would love to program cells as if they were computer chips
  • [H2] How Cambridge Startup Asimov Is Doing Business With 'Genetic Circuits'
  • [H2] How Cambridge Startup Asimov Is Doing Business With 'Genetic Circuits'
  • [H2] Bio-programming toolkit maker Asimov launches with $4.7M from Andreessen Horowitz
  • [H2] Bio-programming toolkit maker Asimov launches with $4.7M from Andreessen Horowitz
  • [H2] Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
  • [H2] Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
  • [H2] Andreessen Horowitz leads seed round in MIT-born 'genetic circuits' startup
  • [H2] Andreessen Horowitz leads seed round in MIT-born 'genetic circuits' startup
  • [H2] Genetic Circuits Startup Asimov Raises Seed Round Led by Andreessen Horowitz
  • [H2] Genetic Circuits Startup Asimov Raises Seed Round Led by Andreessen Horowitz
  • [H2] Asimov
  • [H2] Asimov
  • [H2] Cellular Circuit Computes with DNA
  • [H2] Cellular Circuit Computes with DNA
  • [H2] A programming language for living cells
  • [H2] A programming language for living cells
  • [H2] We're hiring at the intersection of biology, engineering, and machine learning.
  • [H3] Biologics
  • [H3] Cell Therapies
  • [H3] Gene Therapies
  • [H3] Host cells
  • [H3] Genetic parts library
  • [H3] Design software
  • [H3] Host cell lines
  • [H3] Genetic parts library
  • [H3] Design software
  • [H3] We provide tools for you to develop a cell line
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We provide tools for you to develop a cell line
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We transfer our platform to your lab
  • [H3] We ship you host cells and grant software access
  • [H3] You design DNA
  • [H3] We ship DNA to you
  • [H3] You perform cell line development
  • [H3] We perform services in our lab
  • [H3] You request a stable cell line
  • [H3] We perform cell line and process development
  • [H3] We collaborate and share progress
  • [H3] We ship you clonal, stable cell lines
  • [H3] We provide tools for you to develop a cell line
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We transfer our platform to your lab
  • [H3] We develop a cell line for you
  • [H3] We ship you host cells and grant software access
  • [H3] You design DNA
  • [H3] We ship DNA to you
  • [H3] You perform cell line development
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We perform services in our lab
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request a stable cell line
  • [H3] We perform cell line and process development
  • [H3] We collaborate and share progress
  • [H3] We ship you clonal, stable cell lines
  • [H3] Everything you need
  • [H3] From our lab to yours
  • [H3] We use our own platform every day

Images

Nous avons trouvé 285 image(s) sur cette page Web.

214 attribut(s) alt sont vides ou manquants. Ajouter un texte alternatif permet aux moteurs de recherche de mieux comprendre le contenu de vos images.

Ratio texte/HTML

Ratio : 11%

le ratio de cette page texte/HTML est au-dessous de 15 pour cent, ce qui signifie que votre site manque de contenu textuel.

Flash

Parfait, aucun contenu FLASH n'a été détecté sur cette page.

Iframe

Dommage, vous avez des Iframes sur vos pages Web, cela signifie que son contenu ne peut pas être indexé par les moteurs de recherche.

Réécriture d'URLs

Bien. Vos liens sont optimisés!

Tiret bas dans les URLs

Parfait! Aucuns soulignements détectés dans vos URLs.

Liens dans la page

Nous avons trouvé un total de 4 lien(s) dont 0 lien(s) vers des fichiers

Texte d'ancre Type Juice
Biologics Interne Passing Juice
Cell Therapies Interne Passing Juice
Gene Therapies Interne Passing Juice
Sign up Interne Passing Juice

Mots-clefs

Nuage de mots-clefs

read cells cell design blog line asimov development more software

Cohérence des mots-clefs

Mot-clef Contenu Titre Mots-clefs Description Niveaux de titre
cell 113
more 86
asimov 85
read 79
line 79

Ergonomie

Url

Domaine : asimov.com

Longueur : 10

Favicon

Génial, votre site web dispose d'un favicon.

Imprimabilité

Aucun style CSS pour optimiser l'impression n'a pu être trouvé.

Langue

Bien. Votre langue est : en.

Dublin Core

Cette page ne profite pas des métadonnées Dublin Core.

Document

Doctype

HTML 5

Encodage

Parfait. Votre charset est UTF-8.

Validité W3C

Erreurs : 0

Avertissements : 0

E-mail confidentialité

Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.

HTML obsolètes

Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.

Astuces vitesse

Excellent, votre site n'utilise pas de tableaux imbriqués.
Mauvais, votre site web utilise des styles css inline.
Génial, votre site web contient peu de fichiers CSS.
Mauvais, votre site web contient trop de fichiers javascript (plus de 6).
Parfait : votre site tire parti de gzip.

Mobile

Optimisation mobile

Icône Apple
Méta tags viewport
Contenu FLASH

Optimisation

Sitemap XML

Votre site web dispose d’une sitemap XML, ce qui est optimal.

https://www.asimov.com/sitemap.xml

Robots.txt

https://asimov.com/robots.txt

Votre site dispose d’un fichier robots.txt, ce qui est optimal.

Mesures d'audience

Votre site web dispose d’une outil d'analytics, ce qui est optimal.

   Google Analytics

PageSpeed Insights

Dispositif
Les catégories

Free SEO Testing Tool

Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web